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Introduction {#ehf212252-sec-0004}
============

Inter‐ethnic differences in the incidence, symptoms, underlying pathophysiology, and treatment of heart failure (HF) have been described.[1](#ehf212252-bib-0001){ref-type="ref"}, [2](#ehf212252-bib-0002){ref-type="ref"}, [3](#ehf212252-bib-0003){ref-type="ref"}, [4](#ehf212252-bib-0004){ref-type="ref"} However, most epidemiological studies and therapeutic trials have focused exclusively on Caucasian populations, and available data on HF in Asian populations are scarce.[5](#ehf212252-bib-0005){ref-type="ref"}

Previously, Asian HF patients have been reported to have lower mortality rates than did their Caucasian peers.[6](#ehf212252-bib-0006){ref-type="ref"} Higher rates of HF with a preserved ejection fraction (HFpEF) within Asian patients together with higher rates of co‐morbidities such as hypertension, with lower rates of documented myocardial infarction, have also been claimed.[7](#ehf212252-bib-0007){ref-type="ref"}

N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) is the best‐validated biomarker in risk stratification and management of HF.[8](#ehf212252-bib-0008){ref-type="ref"}, [9](#ehf212252-bib-0009){ref-type="ref"}, [10](#ehf212252-bib-0010){ref-type="ref"} B‐type cardiac natriuretic peptide (BNP) and NT‐proBNP have proven their prognostic power in patients with HF across the entire spectrum of ejection fraction.[11](#ehf212252-bib-0011){ref-type="ref"} A recent study showed that Asian‐American and African‐American HF patients have higher BNP levels than did their Caucasian peers and that predictive value for in‐hospital mortality was similar between ethnicities in an acute HF population.[12](#ehf212252-bib-0012){ref-type="ref"} Furthermore, NT‐proBNP had higher discriminatory power for identifying HF in Asian dyspnoeic individuals in the emergency department than in Caucasian dyspnoeic individuals.[13](#ehf212252-bib-0013){ref-type="ref"} However, no previous reports compare results from multi‐ethnic populations with those from stable HF in Asian and Western settings. Therefore, we report the clinical associations and prognostic performance of NT‐proBNP in Asian and Caucasian patients with chronic HF.

Methods {#ehf212252-sec-0005}
=======

Study design and population {#ehf212252-sec-0006}
---------------------------

Data were combined from the studies of Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) and the Singapore Heart Failure Outcomes and Phenotypes (SHOP).[14](#ehf212252-bib-0014){ref-type="ref"}, [15](#ehf212252-bib-0015){ref-type="ref"}, [16](#ehf212252-bib-0016){ref-type="ref"}

In brief, the COACH trial studied the effects of additional intensive nurse‐led support on clinical outcomes in 1023 HF patients.[15](#ehf212252-bib-0015){ref-type="ref"} Overall, the results of the trial were neutral.[14](#ehf212252-bib-0014){ref-type="ref"} NT‐proBNP measurements were available in a sub‐cohort of 546 Caucasian patients measured at discharge (see [Supporting Information](#ehf212252-supitem-0001){ref-type="supplementary-material"}, [*Figure S1*](#ehf212252-supitem-0001){ref-type="supplementary-material"}). The SHOP study prospectively enrolled 1099 HF patients from six different centres in Singapore. The main objective of the SHOP study is to document the prevalence, characteristics, and outcomes of Asian HF patients in Singapore and to determine the relative proportion of HFpEF patients in this population.[16](#ehf212252-bib-0016){ref-type="ref"} The Asian population used in this study refers to a SHOP sub‐cohort of 578 patients with NT‐proBNP measurements available at discharge following hospitalization (see [Supporting Information](#ehf212252-supitem-0001){ref-type="supplementary-material"}, [*Figure S1*](#ehf212252-supitem-0001){ref-type="supplementary-material"}). Inclusion and exclusion criteria were similar for both studies, which both included patients \>18 years of age, either presenting as new onset HF or having previous HF hospitalizations.[15](#ehf212252-bib-0015){ref-type="ref"}, [16](#ehf212252-bib-0016){ref-type="ref"} In both studies, blood sampling for NT‐proBNP assay was performed at or around discharge after hospitalization for acute decompensated HF.[15](#ehf212252-bib-0015){ref-type="ref"}, [16](#ehf212252-bib-0016){ref-type="ref"} Only participants recruited as inpatients were included in this report. This study complies with the Declaration of Helsinki, local medical ethics committees approved the study, and all patients provided written informed consent.

Outcome {#ehf212252-sec-0007}
-------

The endpoint analysed was a combined outcome of all‐cause mortality or HF hospitalizations within 18 months. In both studies, endpoints were adjudicated by an independent committee.

Study and laboratory measurements {#ehf212252-sec-0008}
---------------------------------

Blood samples, echocardiography, and all other data were obtained at discharge from index hospitalization for both COACH and SHOP. HFpEF was defined by a left ventricular ejection fraction (LVEF) of ≥50%, and heart failure with a reduced ejection fraction (HFrEF) by an LVEF \< 40%. Recently, patients with an intermediate LVEF (HF with a mid‐range ejection fraction) have been considered to be a specific patient group and were, therefore, left out of the definition of HFrEF and HFpEF but were included in the analyses on the total population in this study.[17](#ehf212252-bib-0017){ref-type="ref"} Assessment of LVEF was performed at admission or within 6 months prior to admission. Measurements of NT‐proBNP were performed on the Elecsys proBNP ECLIA platform (Roche Diagnostics, Mannheim, Germany) in both the SHOP and COACH cohorts. This assay has intra‐assay and inter‐assay coefficients of variation of 4% and 5%, respectively. The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease formula.[18](#ehf212252-bib-0018){ref-type="ref"}

Statistical analysis {#ehf212252-sec-0009}
--------------------

Continuous variables are presented as medians with interquartile range or means ± SD, where appropriate. Categorical variables are presented as numbers with percentages. Inter‐group differences were tested using Student\'s *t*‐test or Mann--Whitney U‐test for continuous variables or χ^2^ test for categorical variables.

We compared absolute values of NT‐proBNP between ethnicities. For all subsequent (Cox) regression analysis, NT‐proBNP was log2 transformed. The following results for NT‐proBNP should be interpreted as per doubling (e.g. 2--4 and 4--8). An interaction analysis was performed to assess if the relationship between individual clinical variables and NT‐proBNP levels differed between ethnicities. Univariable linear regression analysis was performed separately for Caucasians and Asians with NT‐proBNP as the dependent variable. Multivariable adjustment was then performed for factors known to influence NT‐proBNP levels including age, sex, body mass index (BMI), LVEF, New York Heart Association class, previous myocardial infarction, systolic blood pressure, a history of atrial fibrillation, and eGFR.[19](#ehf212252-bib-0019){ref-type="ref"}, [20](#ehf212252-bib-0020){ref-type="ref"}, [21](#ehf212252-bib-0021){ref-type="ref"}, [22](#ehf212252-bib-0022){ref-type="ref"}, [23](#ehf212252-bib-0023){ref-type="ref"}, [24](#ehf212252-bib-0024){ref-type="ref"}

Cox regression analysis (including interaction analysis in univariable and multivariable models) was performed to further investigate the possible differential association of NT‐proBNP with outcome between different ethnicities. Multivariable models were produced based on significant differences at baseline between ethnicities as well as incorporating known clinically meaningful variables. Model fit was tested using the Hosmer--Lemeshow goodness‐of‐fit test. Additionally, to graphically depict the relationship between ethnicity and the primary outcome, Kaplan--Meier curves stratified by ethnicity were produced. Differences were tested using the log‐rank test. For multivariable Cox regression analysis, the proportional hazards assumption was tested using Schoenfeld residuals and found to be valid. We have provided results of continuous net reclassification analysis to study whether NT‐proBNP significantly improves a model of clinical variables equally in Asian and Caucasian HF patients. Furthermore, we studied the ability of NT‐proBNP to predict outcome on top of a clinical model using the area under the receiver operating characteristic curve. Tests were performed two sided, and a *P*‐value of \<0.05 was considered significant. All statistical analyses were performed using STATA version 13.0 (StataCorp LP, College Station, Texas, USA).

Results {#ehf212252-sec-0010}
=======

Baseline characteristics {#ehf212252-sec-0011}
------------------------

Baseline demographic and clinical characteristics of Asian and Caucasian patients are presented in *Table* [1](#ehf212252-tbl-0001){ref-type="table-wrap"}. Asian patients were younger and less often female than were their Caucasian peers. Additionally, Asian patients had a lower BMI and a better renal function and an overall lower burden of chronic obstructive pulmonary disease, atrial fibrillation, and peripheral vascular disease, while having higher rates of diabetes mellitus and hypertension (*Table* [1](#ehf212252-tbl-0001){ref-type="table-wrap"}). Furthermore, Asian HF patients were more often treated with beta‐blockers (*Table* [1](#ehf212252-tbl-0001){ref-type="table-wrap"}). Despite these differences, absolute plasma concentrations of NT‐proBNP in Asian and Caucasian patients were similar (*P* = 0.514; *Figure* [1](#ehf212252-fig-0001){ref-type="fig"}). After correcting for clinical characteristics influencing NT‐proBNP levels including age, sex, BMI, eGFR, systolic blood pressure, history of atrial fibrillation, and usage of angiotensin‐converting enzyme inhibitors, diuretics, and beta‐blockers, NT‐proBNP levels were equal between Caucasians and Asians (*β* = 0.045, *P* = 0.161, for Asian compared with Caucasian HF patients).

###### 

Baseline characteristics

                                    Total cohort (*n* = 1124)   Caucasian (*n* = 546)   Asian (*n* = 578)      *P* value     
  --------------------------------- --------------------------- ----------------------- ---------------------- ------------- -------------
  Demographics                                                                                                               
  Age (years)                       66.9 (12.3)                 70.7 (11.2)             63.2 (12.3)            **\<0.001**   
  Female sex, *n* (%)               362 (32.1%)                 210 (38.5%)             152 (26.3%)            **\<0.001**   
  NYHA class, *n* (%)               I/II                        689 (62.2%)             257 (47.4%)            432 (76.3%)   **\<0.001**
                                    III                         391 (35.3%)             271 (50.0%)            120 (21.2%)   
                                    IV                          28 (2.5%)               14 (2.6%)              14 (2.5%)     
  BMI (kg/m^2^)                     26.6 (5.5)                  27.1 (5.5)              26.1 (5.5)             **0.004**     
  Systolic blood pressure (mmHg)    119.3 (20.2)                118.1 (21.0)            120.3 (19.3)           0.066         
  Diastolic blood pressure (mmHg)   68.9 (12.1)                 68.6 (12.2)             69.2 (12.1)            0.43          
  Heart rate (b.p.m.)               76.0 (13.9)                 74.6 (13.3)             77.4 (14.3)            **\<0.001**   
  LVEF (%)                          29.0 (20.0, 42.0)           30.0 (22.0, 40.0)       28.0 (20.0, 45.0)      0.990         
  HFpEF, *n* (%)                    169 (18.5%)                 49 (12.7%)              118 (22.5%)            **\<0.001**   
  Medical history, *n* (%)                                                                                                   
  Myocardial infarction             388 (39.7%)                 215 (39.4%)             173 (40.0%)            0.830         
  Hypertension                      676 (60.4%)                 240 (44.0%)             436 (76.1%)            **\<0.001**   
  COPD                              194 (17.3%)                 147 (26.9%)             47 (8.2%)              **\<0.001**   
  Atrial fibrillation               394 (35.2%)                 251 (46.0%)             143 (24.9%)            **\<0.001**   
  Diabetes mellitus                 503 (44.8%)                 162 (29.7%)             341 (59.2%)            **\<0.001**   
  Peripheral vascular disease       130 (11.6%)                 91 (16.7%)              39 (6.8%)              **\<0.001**   
  Stroke                            147 (13.1%)                 83 (15.2%)              64 (11.1%)             **0.040**     
  Prior medication, *n* (%)                                                                                                  
  ACE‐inhibitors                    723 (65.0%)                 394 (72.2%)             329 (58.1%)            **\<0.001**   
  ARB                               203 (18.3%)                 62 (11.4%)              141 (24.9%)            **\<0.001**   
  ACE‐inhibitors and/or ARB         911 (81.9%)                 449 (82.2%)             462 (81.6%)            0.790         
  Beta‐blocker                      861 (77.4%)                 372 (68.1%)             489 (86.4%)            **\<0.001**   
  Aldosterone antagonists           535 (48.1%)                 296 (54.2%)             239 (42.2%)            **\<0.001**   
  Diuretics                         1039 (93.4%)                522 (95.6%)             517 (91.3%)            **0.004**     
  Digoxin                           325 (29.2%)                 177 (32.4%)             148 (26.1%)            **0.022**     
  Laboratory                                                                                                                 
  eGFR (mL/min/1.73 m^2^)           57.8 (30.2)                 54.1 (19.6)             61.3 (37.1)            **\<0.001**   
  Potassium (mEq/L)                 4.1 (3.8, 4.5)              4.2 (3.9, 4.6)          4.0 (3.7, 4.4)         **\<0.001**   
  Sodium (mEq/L)                    138.0 (136.0, 141.0)        139.0 (136.0, 142.0)    138.0 (136.0, 140.0)   **\<0.001**   

ACE, angiotensin‐converting enzyme; ARB, angiotensin‐II receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HFpEF, heart failure with a preserved ejection fraction; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association. Data in bold are *P*‐values \<0.05.

![Boxplots showing N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) levels in Asian and Caucasian heart failure patients.](EHF2-5-279-g001){#ehf212252-fig-0001}

N‐terminal pro‐B‐type natriuretic peptide and clinical variables {#ehf212252-sec-0012}
----------------------------------------------------------------

Univariable and multivariable associations between levels of NT‐proBNP and clinical variables are shown in *Table* [2](#ehf212252-tbl-0002){ref-type="table-wrap"}. In univariable analysis, NT‐proBNP levels were more strongly associated with the male sex in Asians than in Caucasians (*β* = −0.033, *P* = 0.442, in Caucasians; *β* = −0.137, *P* = 0.001, in Asians; *P* ~interaction~ = 0.046); however, no difference in levels of NT‐proBNP between sexes were observed after correcting for the presence of HFpEF in both Asians and Caucasians. Equal associations were found between levels of NT‐proBNP and clinical covariates such as a history of atrial fibrillation, hypertension, BMI, LVEF, and eGFR in both Asians and Caucasians (*P* ~interaction~ all \>0.05). The *R* ^2^ for the multivariable model in Caucasian HF patients (0.17) was lower than in Asian HF patients (0.29).

###### 

Clinical associations of N‐terminal pro‐B‐type natriuretic peptide

                                Caucasian          Asian              *P*‐value (interaction)                      
  ----------------------------- ------------------ ------------------ ------------------------- ------------------ -----------
  Demographics                                                                                                     
  Age                           0.114 (0.008)      0.055 (0.275)      0.108 (0.009)             0.155 (0.001)      0.890
  Female sex                    −0.033 (0.442)     0.014 (0.756)      −0.137 (0.001)            −0.013 (0.752)     **0.046**
  NYHA class                    0.127 (0.003)      0.081 (0.085)      0.140 (0.001)             0.108 (0.004)      0.542
  BMI                           −0.262 (\<0.001)   −0.188 (\<0.001)   −0.272 (\<0.001)          −0.193 (\<0.001)   0.588
  Heart rate                    0.073 (0.091)      0.064 (0.169)      0.045 (0.280)             0.016 (0.678)      0.642
  LVEF                          −0.253 (\<0.001)   −0.259 (\<0.001)   −0.345 (\<0.001)          −0.456 (\<0.001)   0.258
  HFpEF                         −0.232 (\<0.001)   −0.064 (0.457)     −0.376 (\<0.001)          −0.238 (0.007)     0.076
  Medical history                                                                                                  
  Myocardial infarction         0.063 (0.140)      −0.029 (0.547)     0.116 (0.015)             0.031 (0.475)      0.361
  Peripheral vascular disease   0.055 (0.199)      0.019 (0.685)      0.095 (0.022)             0.090 (0.015)      0.216
  Hypertension                  0.041 (0.335)      0.073 (0.128)      −0.059 (0.158)            −0.043 (0.266)     0.087
  Atrial fibrillation           0.051 (0.231)      0.033 (0.491)      0.094 (0.023)             0.124 (0.001)      0.323
  Diabetes                      0.000 (0.991)      0.051 (0.278)      0.020 (0.625)             0.037 (0.327)      0.728
  Laboratory                                                                                                       
  eGFR                          −0.219 (\<0.001)   −0.223 (\<0.001)   −0.223 (\<0.001)          −0.185 (\<0.001)   0.061

BMI, body mass index; eGFR, estimated glomerular filtration rate; HFpEF, heart failure with a preserved ejection fraction; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

Explanatory note: univariable and multivariable associations for between clinical variables and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) levels are shown. The *P*‐value for interaction is the interaction between ethnicity (Asian and Caucasian) and the clinical variable for the association with NT‐proBNP. Data in bold are *P*‐values \<0.05.

Corrected for age, sex, BMI, LVEF, systolic blood pressure, eGFR, and a history of atrial fibrillation.

Outcome in Asian and Caucasian heart failure patients {#ehf212252-sec-0013}
-----------------------------------------------------

In the entire cohort, 507 (45%) patients \[including 273 (47%) Asians\] incurred the primary composite outcome. Asian patients reached the primary combined outcome of all‐cause mortality or HF hospitalizations at 18 months more often than did their Caucasian counterparts \[hazard ratio (HR) 1.35; 95% confidence interval (CI) 1.13--1.60; *P* = 0.001\]. Also after multivariable correction, Asian patients were more often subject to all‐cause mortality or HF rehospitalizations over 18 months (HR 1.36; 95% CI 1.08--1.72; *P* = 0.009, see [Supporting Information](#ehf212252-supitem-0001){ref-type="supplementary-material"}, [*Table S1*](#ehf212252-supitem-0001){ref-type="supplementary-material"} and [*Figure S2*](#ehf212252-supitem-0001){ref-type="supplementary-material"}). For all‐cause mortality alone, 154 (28%) Caucasian HF patients died within 18 months compared with 102 (18%) Asian patients (*P* \< 0.001).

N‐terminal pro‐B‐type natriuretic peptide levels and outcome {#ehf212252-sec-0014}
------------------------------------------------------------

The association of NT‐proBNP with the primary combined outcome was similar (*P* ~interaction~ = 0.631) in Asians (HR 1.56; 95% CI 1.29--1.89; *P* \< 0.001) and Caucasians in both unadjusted and adjusted analyses (HR 1.28; 95% CI 1.21--1.35, *Table* [3](#ehf212252-tbl-0003){ref-type="table-wrap"} and *Figure* [2](#ehf212252-fig-0002){ref-type="fig"}; and HR 1.33; 95% CI 1.16--1.54; *P* \< 0.001, *Table* [3](#ehf212252-tbl-0003){ref-type="table-wrap"} and *Figure* [3](#ehf212252-fig-0003){ref-type="fig"}, respectively). The predictive value of NT‐proBNP in patients with HFrEF and HFpEF was similar in Asian and Caucasian patients specifically; NT‐proBNP had equal predictive power in both HFrEF and HFpEF subgroups (*P* ~interaction~ \> 0.05 across univariable and multivariable models for both Asian and Caucasians) for the combined outcome of death and HF hospitalization (*Table* [3](#ehf212252-tbl-0003){ref-type="table-wrap"}). In multivariable analysis, NT‐proBNP remained equally predictive for the combined endpoint in both Asian and Caucasian HFrEF and HFpEF patients (see [Supporting Information](#ehf212252-supitem-0001){ref-type="supplementary-material"}, [*Figure S3*](#ehf212252-supitem-0001){ref-type="supplementary-material"}). Results were similar for all‐cause mortality alone (see [Supporting Information](#ehf212252-supitem-0001){ref-type="supplementary-material"}, [*Table S2*](#ehf212252-supitem-0001){ref-type="supplementary-material"}). When exploring subgroup associations with outcome in both Asian and Caucasian HF patients, no significant differences were found (*P*‐value for interaction all \>0.05; see [Supporting Information](#ehf212252-supitem-0001){ref-type="supplementary-material"}, [*Figures S4*](#ehf212252-supitem-0001){ref-type="supplementary-material"} and [*S5*](#ehf212252-supitem-0001){ref-type="supplementary-material"}). The receiver operating characteristic curve of the clinical model (Model 3 from *Table* [3](#ehf212252-tbl-0003){ref-type="table-wrap"}) increased from 0.65 to 0.69 when NT‐proBNP was added in Asian patients (*P* \< 0.001) and from 0.70 to 0.72 in Caucasian patients (*P* = 0.037). Net‐reclassification analysis showed that both Asian \[net reclassification index (NRI) 0.377, *P* \< 0.001\] and Caucasian (NRI 0.325, *P* \< 0.001) patients with HF were significantly reclassified after adding NT‐proBNP to a model of clinical variables (Model 3, *Table* [3](#ehf212252-tbl-0003){ref-type="table-wrap"}).

###### 

Cox regression analysis of N‐terminal pro‐B‐type natriuretic peptide corrected for ethnicity

  Adjustments   Cox HR[a](#ehf212252-note-0009){ref-type="fn"} (95% CI)   *P*‐value   Total   Caucasian   Asian
  ------------- --------------------------------------------------------- ----------- ------- ----------- -------
  Univariable   1.28 (1.21--1.35)                                         \<0.001     NA      0.338       0.077
  Ethnicity     1.28 (1.21--1.35)                                         \<0.001     0.631   NA          NA
  Model 1       1.26 (1.19--1.33)                                         \<0.001     0.520   0.865       0.092
  Model 2       1.23 (1.15--1.31)                                         \<0.001     0.825   0.411       0.583
  Model 3       1.28 (1.18--1.39)                                         \<0.001     0.719   0.558       0.776

CI, confidence interval; HF, heart failure; HR, hazard ratio.

Model 1: Ethnicity, Age; Sex.

Model 2: Model 1; body mass index; estimated glomerular filtration rate; systolic blood pressure; history of peripheral vascular disease; chronic obstructive pulmonary disease; diabetes; atrial fibrillation; myocardial infarction, and New York Heart Association class.

Model 3: Model 2; left ventricular ejection fraction; usage of aldosterone antagonists; diuretics; digoxin; beta‐blockers; angiotensin‐converting enzyme inhibitors; angiotensin‐II receptor blockers.

Hazard ratios are per doubling of levels of N‐terminal pro‐B‐type natriuretic peptide.

![Kaplan--Meier curves showing the relationship of N‐terminal pro‐B‐type natriuretic peptide levels with outcome for the total cohort, Caucasian patients, and Asian patients.](EHF2-5-279-g002){#ehf212252-fig-0002}

![Receiver operating characteristic curves for a clinical model, N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), and a clinical model + NT‐proBNP for predicting the primary combined outcome in Asian (A) and Caucasian (B) patients.](EHF2-5-279-g003){#ehf212252-fig-0003}

Discussion {#ehf212252-sec-0015}
==========

This analysis shows that NT‐proBNP is a strong and independent predictor of adverse outcome in both Asian and Caucasian HF patients. In a similar clinical setting of stable HF, Asian HF patients have NT‐proBNP similar to that of their Caucasian peers. For a given relative increase of NT‐proBNP, outcome is equally poor in both Asian and Caucasian patients. This holds true in both HFpEF and HFrEF, regardless of ethnicity. Additionally, the associations of NT‐proBNP with its prime well‐recognized drivers are similar across ethnicities. These findings have clinical implications, namely, that a relative NT‐proBNP increase in both Asian and Caucasian patients can be interpreted similarly. Furthermore, it is likely that NT‐proBNP can be used for selection of patients at high risk for adverse outcomes amongst both Asian and Caucasian ethnicities.

In this study, Asian HF patients differed significantly from their Caucasian counterparts. They were younger yet had more adverse outcomes. With regard to co‐morbidities, Asian patients had significantly higher rates of diabetes and hypertension, while having lower rates of renal impairment and atrial fibrillation. Additionally, they had lower BMIs than did their Caucasian peers. Similar differences with regard to diabetes and atrial fibrillation have been previously observed in an earlier study involving both Asian and Caucasian subjects.[12](#ehf212252-bib-0012){ref-type="ref"} Despite greater age and burden of co‐morbidities, we found that Caucasian HF patients performed better on the primary combined outcome than did Asian HF patients. Nevertheless, Caucasian HF patients had higher mortality rates than did their Asian peers, suggesting that the difference between ethnicities for the combined outcome is mainly driven by higher HF rehospitalization rates. Higher mortality rates in Caucasian patients are potentially explained by the lower rates of beta‐blocker usage in the Caucasian patients in this study. The difference in HF rehospitalizations can be explained by differences in health‐care‐seeking behaviours as well as differences in dosages and effectiveness of guideline‐directed treatment in Asian HF patients, which deserves further study.[25](#ehf212252-bib-0025){ref-type="ref"}, [26](#ehf212252-bib-0026){ref-type="ref"}, [27](#ehf212252-bib-0027){ref-type="ref"} Additionally, ethnic differences can potentially be explained by genetic differences rather than race *per se*. Yet in the absence of genetic data, race provides a good surrogate parameter.[28](#ehf212252-bib-0028){ref-type="ref"}

Median NT‐proBNP levels were similar in Asian and Caucasian HF patients. Also, clinical characteristics known for influencing NT‐proBNP levels had similar effects. Clinical determinants of BNP levels have been previously found to be relatively similar across ethnicities.[12](#ehf212252-bib-0012){ref-type="ref"} Nevertheless, discriminatory power of NT‐proBNP for acute HF is superior in Asian acute HF patients than in Caucasian acute HF patients in the emergency department.[13](#ehf212252-bib-0013){ref-type="ref"} NT‐proBNP levels were similar in our study between Asian and Caucasian patients despite differences in distribution of key drivers of NT‐proBNP levels between Asians such as atrial fibrillation and BMI. This suggests that, overall, the drivers of NT‐proBNP levels were balanced between Asian and Caucasian HF patients and that NT‐proBNP is similarly prognostic irrespective of the exact combination and proportional magnitude of drivers for production and clearance of plasma NT‐proBNP concentrations. Nevertheless, uncaptured confounders such as nutritional status and differences in health‐care systems and nutritional status might influence NT‐proBNP levels.[29](#ehf212252-bib-0029){ref-type="ref"}

NT‐proBNP was similarly associated with both HF rehospitalizations and all‐cause mortality across ethnicities. This finding is in line with an earlier report in acute HF patients, in which levels of BNP measured at admission were found to hold equal predictive value for in‐hospital mortality and length of stay.[12](#ehf212252-bib-0012){ref-type="ref"} Additionally, several key studies have evaluated the predictive value of BNP in Asian populations and showed that BNP is a key predictor of outcomes in these patients.[30](#ehf212252-bib-0030){ref-type="ref"}, [31](#ehf212252-bib-0031){ref-type="ref"}, [32](#ehf212252-bib-0032){ref-type="ref"} Also, NT‐proBNP levels had equal predictive value in both HFpEF and HFrEF. This has been previously reported in a Caucasian population.[11](#ehf212252-bib-0011){ref-type="ref"} This suggests that clinical applications of NT‐proBNP are similar in both Asian and Caucasian populations. Interestingly, values of NT‐proBNP have been shown to be higher in patients with HFrEF compared with HFpEF, yet the predictive value of NT‐proBNP is similar.[11](#ehf212252-bib-0011){ref-type="ref"} Outcome of patients with HFpEF was previously found to be better than that of patients with HFrEF in the MAGGIC meta‐analysis study.[33](#ehf212252-bib-0033){ref-type="ref"} This might in part be explained by lower NT‐proBNP levels; nevertheless, there might be different factors currently unknown that are driving the mortality in HFpEF.[34](#ehf212252-bib-0034){ref-type="ref"}, [35](#ehf212252-bib-0035){ref-type="ref"} Of note, sensitivity and specificity for a given level of NT‐proBNP were comparable between Asian and Caucasian HF patients.

NT‐proBNP is equally prognostic in both Asian and Caucasian populations. This is despite striking inter‐ethnic differences in the mean level (e.g. younger age in Asians) or prevalence (e.g. far more frequent atrial fibrillation in Caucasians) of key background drivers for plasma NT‐proBNP. Notably, each driver exhibits similar strength and slope of association with NT‐proBNP between ethnicities. The findings suggest that clinical applications of NT‐proBNP measurements in diagnosis and management of HF will be similarly effective across ethnicities. Secondly, application of NT‐proBNP as an entry criterion for enrichment of event rates in future trials is equally applicable to Caucasians and Asians. With ethnic differences with regard to treatment response and outcome becoming ever more apparent, future HF trials will most probably be more inclusive of non‐western ethnicities. The findings of this study suggest that NT‐proBNP is equally valuable as an epidemiologic and clinical tool in both Asian and Caucasian HF patients.

Limitations {#ehf212252-sec-0016}
===========

This study is a *post hoc* analysis with all limitations coming with that, including potential selection bias. Since no data are available on treatment during admission for HF prior to discharge, this might confound some of the reported findings. No information was available on difference in nutritional status, although differences in health‐care systems between Singapore and the Netherlands might have influenced NT‐proBNP levels. In this context, patients in this study cover a grey area between acute decompensated and chronic HF patients. Corroboration of our findings will require further studies in independent Asian and Caucasian HF cohorts.

Conclusions {#ehf212252-sec-0017}
===========

NT‐proBNP has equal predictive power in both Caucasian and Asian HF populations at discharge after admission for acute HF. Clinical associations with NT‐proBNP do not differ between ethnicities, suggesting that a given value can be similarly interpreted in both Asian and Caucasian HF patients.
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